Context Therapeutics’ (CNTX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a report issued on Friday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

Other equities analysts also recently issued reports about the stock. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a report on Friday. Finally, JMP Securities began coverage on shares of Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 target price for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $6.17.

Context Therapeutics Stock Up 0.2 %

Shares of CNTX opened at $0.77 on Friday. The company has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $1.44. The company has a market capitalization of $57.88 million, a PE ratio of -0.85 and a beta of 2.06. Context Therapeutics has a 52-week low of $0.64 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. On average, research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth about $29,000. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth about $31,000. Shay Capital LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth about $52,000. Clear Harbor Asset Management LLC boosted its stake in shares of Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after purchasing an additional 21,804 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Context Therapeutics in the third quarter worth approximately $89,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.